4.6 Letter

Hydroxychloroquine early in pregnancy and risk of birth defects: don't throw out the baby with the bathwater

Journal

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 224, Issue 5, Pages 548-549

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2020.12.1218

Keywords

-

Funding

  1. Amgen Inc
  2. AstraZeneca
  3. Celgene
  4. GlaxoSmithKline
  5. Janssen Pharmaceuticals, Inc
  6. Pfizer Inc
  7. Regeneron Pharmaceuticals Inc
  8. HoffmannLa RocheGenentech
  9. Genzyme SanofiAventis
  10. TakedaPharmaceutical Company Limited
  11. Sanofi
  12. UCB Pharma, Smyrna, GA
  13. Sun Pharma Global FZE
  14. Gerber Foundation

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available